{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:12Z","timestamp":1786987452422,"version":"build-2736575974"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["WX21A15"],"award-info":[{"award-number":["WX21A15"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.critrevonc.2024.104258","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T22:08:23Z","timestamp":1706825303000},"page":"104258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical pharmacokinetics and drug\u2013drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective"],"prefix":"10.1016","volume":"195","author":[{"given":"Fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-9002","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1515\/dmdi-2014-0026","article-title":"Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src\/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects","volume":"30","author":"Abbas","year":"2015","journal-title":"Drug Metab. Pers. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-012-1987-7","article-title":"Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects","volume":"71","author":"Abbas","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin. Pharm."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104258_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/0091270010387427","article-title":"Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects","volume":"51","author":"Abbas","year":"2011","journal-title":"J. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104258_bib5","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.clinthera.2012.07.006","article-title":"Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects","volume":"34","author":"Abbas","year":"2012","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40261-013-0103-z","article-title":"A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects","volume":"33","author":"Abbas","year":"2013","journal-title":"Clin. Drug Invest."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pharep.2018.10.018","article-title":"Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction","volume":"71","author":"Abdelgalil","year":"2019","journal-title":"Pharm. Rep."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104258_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212516","article-title":"Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?","volume":"22","author":"Abdulmawjood","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104258_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.leukres.2017.11.012","article-title":"Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients","volume":"64","author":"Abumiya","year":"2018","journal-title":"Leuk. Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug Metab. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00228-021-03266-y","article-title":"Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib","volume":"78","author":"Adiwidjaja","year":"2022","journal-title":"Eur. J. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11095-020-02834-8","article-title":"Physiologically-based pharmacokinetic predictions of the effect of curcumin on metabolism of imatinib and bosutinib: in vitro and in vivo disconnect","volume":"37","author":"Adiwidjaja","year":"2020","journal-title":"Pharm. Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib13","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bcp.14303","article-title":"Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach","volume":"86","author":"Adiwidjaja","year":"2020","journal-title":"Br. J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib14","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1002\/jcp.27505","article-title":"Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches","volume":"234","author":"Asnafi","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au","year":"2014","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104258_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.200702-178OC","article-title":"Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice","volume":"176","author":"Azuma","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med"},{"issue":"37","key":"10.1016\/j.critrevonc.2024.104258_bib18","first-page":"79","article-title":"Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia","volume":"1","author":"Binzaid","year":"2021","journal-title":"Gulf J. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","article-title":"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects","volume":"53","author":"Bolton","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/ejh.13418","article-title":"Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden","volume":"105","author":"Boons","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104258_bib21","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1200\/JCO.2005.05.246","article-title":"Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib","volume":"23","author":"Bornh\u00e4user","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mayocp.2012.10.020","article-title":"Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents","volume":"88","author":"Bowlin","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib23","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2024.104258_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00136","article-title":"Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML","volume":"7","author":"Bugler","year":"2019","journal-title":"Front Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-021-04394-z","article-title":"Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling","volume":"89","author":"Chang","year":"2022","journal-title":"Cancer Chemother. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib","volume":"330","author":"Chen","year":"2009","journal-title":"J. Pharm. Exp. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104258_bib29","first-page":"424","article-title":"Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole","volume":"75","author":"Chen","year":"2020","journal-title":"Pharmazie"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans","volume":"36","author":"Christopher","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2024.104258_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104258_bib34","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104258_bib35","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"10314","key":"10.1016\/j.critrevonc.2024.104258_bib36","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/bcp.15551","article-title":"CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients","volume":"89","author":"Dalle Fratte","year":"2023","journal-title":"Br. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2003.04.004","article-title":"Understanding and preventing drug interactions in elderly patients","volume":"48","author":"Delafuente","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"20 Pt 1","key":"10.1016\/j.critrevonc.2024.104258_bib40","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin. Cancer Res"},{"issue":"Suppl 2:S1-29","key":"10.1016\/j.critrevonc.2024.104258_bib41","first-page":"quiz S30","article-title":"NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines","volume":"5","author":"Demetri","year":"2007","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/pgs-2016-0012","article-title":"ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib","volume":"17","author":"Dessilly","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: First Approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104258_bib44","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib45","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","article-title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","volume":"54","author":"Dutreix","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000089990","article-title":"Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma","volume":"69","author":"Eckel","year":"2005","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J. Clin. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat. Rev."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104258_bib50","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"van Erp","year":"2007","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","article-title":"Effect of St John's wort on imatinib mesylate pharmacokinetics","volume":"76","author":"Frye","year":"2004","journal-title":"Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib52","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/bcp.15650","article-title":"Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients","volume":"89","author":"Fukushi","year":"2023","journal-title":"Br. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamaoncol.2015.50","article-title":"Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.","volume":"1","author":"Gambacorti-Passerini","year":"2015","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000088510","article-title":"Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia","volume":"211","author":"Gambillara","year":"2005","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group","volume":"26","author":"Gibbons","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104258_bib56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2010.05.004","article-title":"Potential drug interactions in elderly cancer patients","volume":"78","author":"Girre","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib58","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1124\/dmd.110.032326","article-title":"Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients","volume":"38","author":"Gong","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin. Pharm. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib60","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib61","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104258_bib62","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.critrevonc.2024.104258_bib63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.03.011","article-title":"Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia","volume":"120","author":"Harivenkatesh","year":"2017","journal-title":"Pharm. Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib64","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib65","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/bega.2001.0249","article-title":"Drug metabolism and drug interactions in the elderly","volume":"15","author":"Herrlinger","year":"2001","journal-title":"Best. Pr. Res Clin. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2024.104258_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics","volume":"12","author":"He","year":"2021","journal-title":"Front Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib67","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib68","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/cts.13285","article-title":"Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104258_bib69","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcph.1926","article-title":"Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment","volume":"61","author":"Hoch","year":"2021","journal-title":"J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib70","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/cts.13252","article-title":"Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.1019","article-title":"Pharmacokinetics of Asciminib When Taken With Imatinib or With Food","volume":"11","author":"Hoch","year":"2022","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-012-1998-4","article-title":"Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia","volume":"71","author":"Hsyu","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cpdd.396","article-title":"Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study","volume":"7","author":"Hsyu","year":"2018","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00228-016-2108-z","article-title":"Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects","volume":"73","author":"Hsyu","year":"2017","journal-title":"Eur. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00228-016-2115-0","article-title":"Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects","volume":"73","author":"Hsyu","year":"2017","journal-title":"Eur. J. Clin. Pharm."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104258_bib76","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104258_bib78","article-title":"Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia","volume":"13","author":"Jiang","year":"2023","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib79","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib80","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FTD.0b013e318292b931","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring","volume":"35","author":"Josephs","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.critrevonc.2024.104258_bib81","first-page":"4479","article-title":"Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathway.","author":"Kadi","year":"2016","journal-title":"Rsc Adv."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib82","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1211\/jpp.58.7.0016","article-title":"Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats","volume":"58","author":"Kajita","year":"2006","journal-title":"J. Pharm. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib84","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1021\/acs.molpharmaceut.7b00257","article-title":"Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP\/ABCB1) and Breast Cancer Resistance Protein (BCRP\/ABCG2)","volume":"14","author":"Kort","year":"2017","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00280-020-04117-w","article-title":"Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects","volume":"86","author":"Kuang","year":"2020","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib87","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell Biochem"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib88","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-08-2253","article-title":"Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment","volume":"15","author":"Lagas","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib89","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.117.246116","article-title":"Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier","volume":"365","author":"Laramy","year":"2018","journal-title":"J. Pharm. Exp. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib90","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib91","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib92","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/jpet.117.243246","article-title":"Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites","volume":"363","author":"Lin","year":"2017","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.critrevonc.2024.104258_bib94","article-title":"Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib95","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","article-title":"Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases","volume":"61","author":"Li","year":"2022","journal-title":"Clin. Pharm."},{"issue":"46","key":"10.1016\/j.critrevonc.2024.104258_bib96","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111451118","article-title":"Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance","volume":"118","author":"Lyczek","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2024.104258_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib98","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","article-title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","volume":"63","author":"Menon-Andersen","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104258_bib99","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"Merkulova","year":"2019","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-022-04466-8","article-title":"Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer","volume":"90","author":"Morita","year":"2022","journal-title":"Cancer Chemother. Pharm."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104258_bib101","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-014-2511-z","article-title":"Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects","volume":"74","author":"Narasimhan","year":"2014","journal-title":"Cancer Chemother. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib103","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cpdd.182","article-title":"Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects","volume":"4","author":"Narasimhan","year":"2015","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib104","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40261-014-0225-y","article-title":"Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects","volume":"34","author":"Narasimhan","year":"2014","journal-title":"Clin. Drug Invest."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.12082","article-title":"Effects of food on the pharmacokinetics of ponatinib in healthy subjects","volume":"38","author":"Narasimhan","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104258_bib106","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcph.109","article-title":"Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects","volume":"53","author":"Narasimhan","year":"2013","journal-title":"J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib107","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-003-0756-z","article-title":"Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules","volume":"53","author":"Nikolova","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib108","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib109","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104258_bib110","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1016\/j.critrevonc.2024.104258_bib111","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: a new step in molecular target therapy","volume":"18","author":"Olivieri","year":"2007","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib112","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib113","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.xphs.2017.03.022","article-title":"Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport","volume":"106","author":"Pahwa","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib114","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40261-020-00921-7","article-title":"Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects","volume":"40","author":"Pena","year":"2020","journal-title":"Clin. Drug Invest."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104258_bib115","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib116","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-200868040-00005","article-title":"Nilotinib","volume":"68","author":"Plosker","year":"2008","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib117","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28041602","article-title":"Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism","volume":"28","author":"Raish","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2024.104258_bib119","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-015-0179-4","article-title":"In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib","volume":"8","author":"Redaelli","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcp.12584","article-title":"Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension","volume":"80","author":"Renard","year":"2015","journal-title":"Br. J. Clin. Pharm."},{"issue":"48","key":"10.1016\/j.critrevonc.2024.104258_bib121","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure","volume":"13","author":"Ridruejo","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104258_bib122","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med Chem."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104258_bib123","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib124","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/annonc\/mdw182","article-title":"Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker","volume":"27","author":"Da Silva","year":"2016","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104258_bib125","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104258_bib126","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1592\/phco.24.16.1508.50958","article-title":"The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate","volume":"24","author":"Smith","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib127","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib128","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-008-0778-7","article-title":"Effect of antacid on imatinib absorption","volume":"63","author":"Sparano","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib129","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3892\/or.2014.3002","article-title":"Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells","volume":"31","author":"Sun","year":"2014","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","article-title":"Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients","volume":"69","author":"Takahashi","year":"2012","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib131","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib132","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib133","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0091270010367428","article-title":"Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants","volume":"51","author":"Tanaka","year":"2011","journal-title":"J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104258_bib134","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-013-2283-x","article-title":"Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers","volume":"72","author":"Tawbi","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104258_bib135","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib136","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"Tiwari","year":"2009","journal-title":"Biochem Pharm."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2024.104258_bib137","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.canlet.2007.10.041","article-title":"Imatinib for hepatocellular cancer--focus on pharmacokinetic\/pharmacodynamic modelling and liver function","volume":"260","author":"Treiber","year":"2008","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib138","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Wang","year":"2008","journal-title":"Br. J. Clin. Pharm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104258_bib139","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104258_bib140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcmd.2016.05.007","article-title":"TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome","volume":"59","author":"Weich","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib141","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib142","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104258_bib143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-2-10","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"2","author":"Wong","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104258_bib144","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/s41375-023-02062-0","article-title":"Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis","volume":"37","author":"Wu","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104258_bib145","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/bdd.1821","article-title":"Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability","volume":"33","author":"Xia","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib146","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1208\/s12248-014-9673-9","article-title":"The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria","volume":"16","author":"Yago","year":"2014","journal-title":"Aaps J."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib147","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2007.08.008","article-title":"Erythroblasts highly express the ABC transporter Bcrp1\/ABCG2 but do not show the side population (SP) phenotype","volume":"114","author":"Yamamoto","year":"2007","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib148","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104258_bib149","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2012.03.008","article-title":"Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry","volume":"895-896","author":"Yang","year":"2012","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-017-3240-x","article-title":"Absorption, metabolism, and excretion of [(14)C]ponatinib after a single oral dose in humans","volume":"79","author":"Ye YE","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib151","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00280-012-1999-3","article-title":"Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers","volume":"71","author":"Yin","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104258_bib152","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/0091270009346061","article-title":"Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib","volume":"50","author":"Yin","year":"2010","journal-title":"J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104258_bib153","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/11538700-000000000-00000","article-title":"Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects","volume":"31","author":"Yin","year":"2011","journal-title":"Clin. Drug Invest."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104258_bib154","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0091270009336137","article-title":"Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants","volume":"50","author":"Yin","year":"2010","journal-title":"J. Clin. Pharm."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2024.104258_bib155","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/j.clinthera.2009.11.015","article-title":"Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study","volume":"31","author":"Yin","year":"2009","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib156","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","article-title":"INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity","volume":"109","author":"Yokota","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104258_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1065130","article-title":"Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models","volume":"13","author":"Yu","year":"2022","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104258_bib158","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104258_bib159","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcph.434","article-title":"Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam","volume":"55","author":"Zhang","year":"2015","journal-title":"J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104258_bib160","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther. Drug Monit."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:52:14Z","timestamp":1760903534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":160,"alternative-id":["S1040842824000015"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104258","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacokinetics and drug\u2013drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104258"}}